Business Update2 Jul 2026, 10:39 am
Aurobindo Pharma Completes Transfer of Domestic Business to Subsidiary
AI Summary
Aurobindo Pharma Ltd has announced the completion of the transfer of its domestic branded generic pharmaceutical formulations products business to its wholly owned subsidiary, Auropharm Limited. This transfer was executed on a slump sale basis as per a Business Transfer Agreement (BTA) signed earlier. The business operations are now officially being conducted under Auropharm Limited, effective from July 1, 2026. This move is part of the company's strategic restructuring to streamline operations and potentially enhance focus on specific business segments.
Key Highlights
- Domestic branded generic business transferred to Auropharm Limited.
- Transfer completed as per Business Transfer Agreement (BTA).
- Effective date of transfer is July 1, 2026.
- Auropharm Limited is a wholly owned subsidiary.
- Transaction executed on a slump sale basis.
Price Impact
More from AUROPHARMA